Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742573 · ClinicalTrials.gov registry record · Phase 2
Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics
A Phase 2 study of Major Depressive Disorder, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 1
- Study location
NCT00742573: Completed Phase 2 study of Major Depressive Disorder, sponsored by New York State Psychiatric Institute.
NCT00742573 is a Phase 2 study of Major Depressive Disorder that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 170 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00742573, a Phase 2 study of Major Depressive Disorder, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
Primary Outcome
Average number of weeks of retention of Hispanics in the treatment of MDD
Conditions Studied
Interventions
- DRUG Antidepressants through Texas Medication Algorithm (TMA)
- BEHAVIORAL Brief Interpersonal Psychotherapy (IPT-B)
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2008-08 |
| Est. Completion | 2014-01-10 |
| Phase | Phase 2 |
What the finished NCT00742573 record still lists
NCT00742573 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Antidepressants through Texas Medication Algorithm (TMA) is the first listed.
NCT00742573 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00742573 about?
NCT00742573 is a clinical study titled "Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics". This study will determine whether combination treatment driven by patient choice is better than standardized medication treatment at retaining and improving Hispanic patients with major depressive disorder.
What is the current status of trial NCT00742573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2008-08. Estimated completion is 2014-01-10.
What conditions does trial NCT00742573 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT00742573?
The interventions under investigation include: Antidepressants through Texas Medication Algorithm (TMA) (DRUG), Brief Interpersonal Psychotherapy (IPT-B) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00742573?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00742573 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00742573's enrollment target sits among peer trials
170 91st of 282 higher than 192 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia